Wednesday, 17 January 2024
A new analysis of trial data on pregnant smokers has found that the regular use of nicotine replacement products during pregnancy is not associated with adverse pregnancy events or poor pregnancy outcomes.
The PREP 2 study used data collected from over 1100 pregnant smokers attending 23 hospitals in England and one stop-smoking service in Scotland to compare pregnancy outcomes in women who did or did not use nicotine in the form of e-cigarettes (EC) or nicotine patches regularly during their pregnancy. The trial recruitment was led by the University of Nottingham’s Smoking in Pregnancy Research Group, and the study was led by experts at Queen Mary University of London.
Researchers took measurements of salivary cotinine levels at baseline and towards the end of pregnancy, and gathered information about each participant’s use of cigarettes or types of NRT, respiratory symptoms, and the birth weight and other data of their babies at birth.
The study found that e-cigarettes were more commonly used in the group studied than nicotine patches (47% compared with 21%), and also confirmed previous unexpected findings that EC use may reduce respiratory infections in vapers, possibly because the main ingredients of EC, aerosol, propylene glycol, and glycerine, have antibacterial effects.
Women who smoked and also used one of the nicotine replacement products during their pregnancy had babies with the same birth weights as women who only smoked, while babies born to women who did not smoke during pregnancy did not differ in birth weight, whether the women did or did not use nicotine products. Regular use of nicotine products was not associated with any adverse effects in mothers or their babies.
Lead researcher, Professor Peter Hajek from the Wolfson Institute of Population Health, Queen Mary University of London, said: "The trial contributes answers to two important questions, one practical and one concerning our understanding of risks of smoking. E-cigarettes helped pregnant smokers quit without posing any detectable risks to pregnancy compared with stopping smoking without further nicotine use. Using nicotine containing aids to stop smoking in pregnancy thus appears safe. The harms to pregnancy from smoking, in late pregnancy at least, seem to be due to other chemicals in tobacco smoke rather than nicotine."
Smoking in pregnancy is a massive public health problem and nicotine containing aids can help pregnant women to stop smoking, but some clinicians are reticent about providing NRT or e-cigarettes in pregnancy. This study provides further, reassuring evidence that tobacco smoke chemicals rather than nicotine are responsible for smoking-related harms, so using nicotine containing aids to quit is vastly preferable to continuing to smoke when pregnant.”
Professor Linda Bauld, Bruce and John Usher Chair in Public Health at the University of Edinburgh and a study co-investigator said: “Clinicians, pregnant women and their families have questions about the safety of using nicotine replacement therapy (NRT) or e-cigarettes during pregnancy. Women who continue to smoke during pregnancy often find it difficult to stop but products like NRT or e-cigarettes can help them to do so. These results suggest that NRT or vaping can be used as part of a quit attempt without adverse effects. Our findings should be reassuring, and provide further important evidence to guide decision-making on smoking cessation during pregnancy.”
The study, conducted by researchers at Queen Mary University of London, University of New South Wales (Australia), the University of Nottingham, St George’s University of London, University of Stirling, University of Edinburgh, and King’s College London, and St George’s University Hospitals NHS Foundation Trust, analysed data collected in the Pregnancy Trial of E-cigarettes and Patches (PREP) randomised controlled trial, funded by the National Institute for Health and Care Research (NIHR).
Story credits
More information is available from Professor Tim Coleman at the University of Nottingham at tim.coleman@nottingham.ac.uk
Notes to editors:
About the University of Nottingham
Ranked 32 in Europe and 16th in the UK by the QS World University Rankings: Europe 2024, the University of Nottingham is a founding member of the Russell Group of research-intensive universities. Studying at the University of Nottingham is a life-changing experience, and we pride ourselves on unlocking the potential of our students. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement.
Nottingham was crowned Sports University of the Year by The Times and Sunday Times Good University Guide 2024 – the third time it has been given the honour since 2018 – and by the Daily Mail University Guide 2024.
The university is among the best universities in the UK for the strength of our research, positioned seventh for research power in the UK according to REF 2021. The birthplace of discoveries such as MRI and ibuprofen, our innovations transform lives and tackle global problems such as sustainable food supplies, ending modern slavery, developing greener transport, and reducing reliance on fossil fuels.
The university is a major employer and industry partner - locally and globally - and our graduates are the second most targeted by the UK's top employers, according to The Graduate Market in 2022 report by High Fliers Research.
We lead the Universities for Nottingham initiative, in partnership with Nottingham Trent University, a pioneering collaboration between the city’s two world-class institutions to improve levels of prosperity, opportunity, sustainability, health and wellbeing for residents in the city and region we are proud to call home.
More news…